iShares Gold Trust vs Nuwellis Inc — how do they compare? iShares Gold Trust trades at $76.83, while Nuwellis Inc trades at $2.9 (market cap $1.09M). The key difference: iShares Gold Trust is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| IAU | NUWE | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Technology |
52-Week High | $101.57 | $527.46 |
52-Week Low | $61.62 | $2.80 |
Market Cap | — | $1.09M |
Enterprise Value | — | -$722.58K |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NUWE trades at $3.00, up 5.26% today, following a 35:1 reverse stock split effective June 26, 2026. The company shows a low P/E of 0.06 and P/S of 0.01, but fundamentals are weak with a -217.22% net income margin and negative ROE. Recent news highlights patent awards and pediatric market expansion, yet cash flow remains negative. Analyst coverage is limited with a split buy/hold consensus.
Outlook is speculative; growth depends on successful commercialization of Aquadex therapy and cost management. Key risks include persistent losses, high cash burn, and competitive pressures. Investors should weigh low valuation against execution risks in the medical technology sector.
Trailing returns across standard periods
Latest headlines on both assets
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →